Clone:
REA279
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MC
Alternative names:
CCR4, CC-CKR-4, CKR4, CMKBR4, CHEMR13, K5-5

Extended validation for CD194 (CCR4) Antibody, anti-human, REAfinity™

Specificity

Epitope competition
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Other clonesOverlap in epitope recognition with REA279
1G1++
L291H4-
Cells were incubated with an excess of purified unconjugated CD194 (CCR4) (REA279) antibody followed by staining with fluorochrome-conjugated antibodies of other known clones against the same marker. Based on the fluorescence signal obtained, the clones were identified as recognizing completely overlapping (++), partially overlapping (+), or completely different epitopes (-) of the marker.

Sensitivity

Performance comparison
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
View details
Flow cytometric comparison of different clones for CD194 (CCR4). Human peripheral blood mononuclear cells (PBMCs) were stained with CD194 (CCR4) antibodies and with a suitable counterstaining. As a control, CD194 (CCR4) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD194 (CCR4). Human peripheral blood mononuclear cells (PBMCs) were stained with CD194 (CCR4) antibodies and with a suitable counterstaining. As a control, CD194 (CCR4) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD194 (CCR4). Human peripheral blood mononuclear cells (PBMCs) were stained with CD194 (CCR4) antibodies and with a suitable counterstaining. As a control, CD194 (CCR4) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD194 (CCR4). Human peripheral blood mononuclear cells (PBMCs) were stained with CD194 (CCR4) antibodies and with a suitable counterstaining. As a control, CD194 (CCR4) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Flow cytometric comparison of different clones for CD194 (CCR4). Human peripheral blood mononuclear cells (PBMCs) were stained with CD194 (CCR4) antibodies and with a suitable counterstaining. As a control, CD194 (CCR4) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Fixation data
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
No fixation
Post fixation
View details
Comparison of staining pattern on non-fixed and fixed cells using CD194 (CCR4) (REA279). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
View details
Comparison of staining pattern on non-fixed and fixed cells using CD194 (CCR4) (REA279). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Comparison of staining pattern on non-fixed and fixed cells using CD194 (CCR4) (REA279). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD194 (CCR4) Antibody, anti-human, REAfinity™

Overview

Clone REA279 recognizes the CD194 antigen, a seven-transmembrane G-protein–coupled receptor also known as C-C chemokine receptor type 4 (CCR4). CD194 is expressed on activated Tʜ2 cells, regulatory T cells, a subset of B cells, activated natural killler (NK) cells, basophils, monocytes, NK cells, and platelets. It is expressed at high levels by skin-infiltrating lymphocytes, at lower levels by lung and synovial fluid lymphocytes, but never by intestinal lymphocytes. CD194 is the specific receptor for the chemokines CCL17 (TARC) and CCL22 (MDC). Human peripheral blood regulatory T cells can be divided into two distinct populations based on the expression of CCR4. The majority of freshly isolated regulatory T cells express CD194 and represent memory-type regulatory T cells, while CD194 regulatory T cells require anti-CD3 antibody–mediated activation to acquire a regulatory activity. Depletion of 194
+
T cells leads to Tʜ1-type polarization of CD4
+
T cells and augmentation of CD8
+
T cell responses to tumor antigens.
Additional information: Clone REA279 displays negligible binding to Fc receptors.

Alternative names

CCR4, CC-CKR-4, CKR4, CMKBR4, CHEMR13, K5-5

Detailed product information

Technical specifications

CloneREA279
Clonalitymonoclonal
Isotyperecombinant human IgG1
Isotype controlREA Control Antibody (S), human IgG1
Hostcell line
Type of antibodyPrimary antibodies, Recombinant antibodies
Specieshuman
AntigenCD194 (CCR4)
Alternative names of antigenCCR4, CC-CKR-4, CKR4, CMKBR4, CHEMR13, K5-5
Molecular mass of antigen [kDa]41
Distribution of antigenT cells, B cells, NK cells, monocytes, T cells, NK cells, B cells, monocytes
Entrez Gene ID1233
RRIDAB_2733352, AB_2751529, AB_2751493, AB_2784038, AB_2784037, AB_2801774, AB_2801765, AB_2801903, AB_2733351

References for CD194 (CCR4) Antibody, anti-human, REAfinity™

Publications

  1. Baatar, D. et al. (2007)
    Human peripheral blood T regulatory cells (Tregs), functionally primed CCR4
    +
    Tregs and unprimed CCR4
    Tregs, regulate effector T cells using FasL.
    J. Immunol. 178(8): 4891-4900
  2. Sallusto, F. et al. (1998) Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J. Exp. Med. 187(6): 875-883
  3. Kunkel, E. J. et al. (2002) Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes. Am. J. Pathol. 160(1): 347-355
  4. Power, C. A. et al. (1995) Molecular cloning and functional expression of a novel CC chemokine receptor cDNA from a human basophilic cell line. J. Biol. Chem. 270(33): 19495-19500

Related products for
CD194 (CCR4) Antibody, anti-human, REAfinity™

3 products available